Irprestan

Irbesartan, the active ingredient in Irprestan, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral administration. It is used to manage high blood pressure and to protect kidney function in patients with diabetic nephropathy, offering a targeted approach to cardiovascular and renal health in adult populations.

GNH USA supplies Irprestan as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide with consistent quality and regulatory adherence.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to lower blood pressure and protect renal function.

- Hypertension: reduces systolic and diastolic blood pressure, decreasing cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. - Proteinuria associated with diabetic kidney disease: lowers urinary protein excretion, indicating renal protection.

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects: - Dizziness: feeling light‑headed, especially after standing quickly. - Headache: mild to moderate head pain. - Fatigue: unusual tiredness or lack of energy. - Nasal congestion: stuffy or runny nose. - Back pain: discomfort in the lower back region.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may impair breathing. - Hyperkalemia: elevated potassium levels that can affect heart rhythm. - Acute kidney injury: sudden decline in renal function. - Hepatic injury: abnormal liver enzyme elevations indicating liver stress.

Before initiating therapy, consider patient‑specific factors and monitor relevant parameters. - Blood pressure monitoring: check regularly to ensure therapeutic targets are met. - Renal function assessment: evaluate serum creatinine and eGFR before and during treatment. - Electrolyte surveillance: monitor potassium levels, especially if combined with potassium‑sparing agents. - Hepatic impairment caution: adjust use in patients with significant liver disease. - Pregnancy avoidance: discontinue if pregnancy is confirmed or planned. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Potassium‑sparing diuretics: risk of severe hyperkalemia. - ACE inhibitors: additive effect on potassium and renal function. - Lithium: increased lithium concentrations, risking toxicity.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect, requiring dose adjustment. - Rifampin: can reduce irbesartan plasma levels, potentially diminishing efficacy.